TOBREX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBREX is a tobramycin ophthalmic solution approved in 1980 for bacterial eye infections. It is a small-molecule aminoglycoside antibiotic delivered as topical drops directly to the eye. The drug works by inhibiting bacterial protein synthesis to treat gram-negative and some gram-positive ocular pathogens.
$0.057MPart D
LOE ApproachingLow commercial intensity with modest Part D volume signals a niche mature product with minimal team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle
Started Dec 2006
0Post-surgical Inflammation
Career Relevance
TOBREX offers limited career momentum given zero linked job postings and approaching loss of exclusivity. Roles are primarily defensive, focused on maintaining market share in a commoditizing ophthalmic segment rather than growth or innovation.
Brand Manager
Worked on TOBREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.